Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C
datasetposted on 03.09.2020, 20:30 by Guangyi Wang, Natalia Dyatkina, Marija Prhavc, Caroline Williams, Vladimir Serebryany, Yujian Hu, Yongfei Huang, Xiangyang Wu, Tongqian Chen, Wensheng Huang, Vivek K. Rajwanshi, Jerome Deval, Amy Fung, Zhinan Jin, Antitsa Stoycheva, Kenneth Shaw, Kusum Gupta, Yuen Tam, Andreas Jekle, David B. Smith, Leonid Beigelman
Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The current standard of care for CHC can achieve cure rates above 95%; however, the drugs in current use are administered for a period of 8–16 weeks. A combination of safe and effective drugs with a shorter treatment period is highly desirable. We report synthesis and biological evaluation of a series of 2′,3′- and 2′,4′-substituted guanosine nucleotide analogues. Their triphosphates exhibited potent inhibition of the HCV NS5B polymerase with IC50 as low as 0.13 μM. In the HCV replicon assay, the phosphoramidate prodrugs of these analogues demonstrated excellent activity with EC50 values as low as 5 nM. A lead compound AL-611 showed high levels of the nucleoside 5′-triphosphate in vitro in primary human hepatocytes and in vivo in dog liver following oral administration.
Read the peer-reviewed publication
triphosphateCHCEC 50 valuesAL -611report synthesisguanosine nucleotide analoguesAnti-HCV Activity5 nMtreatment perioddog livercure ratesliver diseaseHCV NS 5B Polymerase Inhibitorhepatitis C viruscompound AL -6110.13 μ MIC 50Sugar-Modified Guanosine AnaloguesChronic Hepatitis C Chronic hepatitis CHCV replicon assayphosphoramidate prodrugsHCV NS 5B polymerase